ALN-APOC3
ALN-APOC3-hLP-2447
Phase 1 small_molecule completed
Quick answer
ALN-APOC3 for Dyslipidemia is a Phase 1 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Dyslipidemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed